Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus

Tolerance Bio has launched with an oversubscribed $17.2 million seed round and a goal to develop therapies for immune-mediated diseases, from cancer to transplant rejection …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR T-cells. This breakthrough enhances tumor targeting while reducing off-target effects,

November 18, 2024

J&J takes 340B fight with federal government to court

Johnson & Johnson is suing the federal government over its rebuke of the company’s alternative model for 340B drug price discounts. The company asked a

November 14, 2024

Arcturus Therapeutics extends cystic fibrosis treatment deal

Arcturus is advancing the mRNA therapeutic to treat cystic fibrosis. Credit: Magic mine/Shutterstock.com. Arcturus Therapeutics has extended an existing agreement with the Cystic Fibrosis (CF)

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.